Navigation Links
Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc.
Date:7/23/2014

ROCHESTER, N.Y., July 23, 2014 /PRNewswire/ -- The Board of Directors of VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of clinical trial imaging solutions, announced today that Eric T. Converse, 48, has been named president and chief executive officer, effective immediately.  Mr. Converse joined the company's Board of Directors in August 2013 and has held the positions of interim president and chief executive officer since October 25, 2013.

Dr. Charles E. Phelps, Ph.D., chairman of the company's Board of Directors, said, "During the past nine months, Eric has clearly demonstrated his leadership and team-building skills on a number of fronts and has earned the respect and cooperation from VirtualScopics' senior management team, employees, industry thought leaders and customers.  His contributions to the company thus far include: negotiating a global operational and commercialization alliance with IXICO plc, the brain health company, based in the United Kingdom; working closely with VirtualScopics and IXICO senior management to form a joint Scientific Advisory Board to benefit both companies; and the recent opening of a joint office in New Hope, Pennsylvania.  The new office is located in the heart of the big pharma corridor, providing project management teams from both companies the opportunity to work more closely with existing and prospective customers to determine their clinical trial imaging needs."  Dr. Phelps added, "With the assistance of Korn Ferry, International, the Board of Directors conducted an extensive search that brought forward numerous candidates with strong skills and backgrounds, a number of whom eagerly sought the CEO position at VirtualScopics.  In the Board's judgment, the leadership demonstrated by Eric during his term as interim CEO made it clear that he was the best choice to take the Company forward."  

Mr. Converse added, "I am very pleased to be working with this team.  Our focus on our employees and infrastructure investments has shown early results with increases in customer wins that will ultimately lead to improved shareholder value.  As I strongly believe a good team will yield good results, I am extremely excited to continue with this great team and deliver even greater results." Converse continued, "The first six months of 2014 represents the company's best start in terms of bookings and awards outstanding in the history of the company, a testament to the strong commitment and dedication of the entire VirtualScopics team.  We are all excited about our recent alliance with IXICO and the many benefits of this relationship that are already coming to fruition."

Mr. Converse has more than 20 years of hands-on management experience working with early-stage companies across a wide range of industries.  He received his bachelor's degree from Michigan State University and attended Erasmus University in Rotterdam, The Netherlands.

About VirtualScopics, Inc.
VirtualScopics, Inc. (NASDAQ: VSCP) is a leading provider of clinical trial imaging solutions to accelerate drug and medical device development.  For risk-averse, time-constrained Clinical Trial Study Teams, Medical Directors and Imaging Scientists who require quality imaging data delivered on-time, within budget and on a consistent basis, VirtualScopics' clinical trial imaging solutions are an inspired true exception to commonly-accepted services provided by other clinical trial imaging providers.  Because of the scientific and operational flexibility and responsiveness they can offer, VirtualScopics' clinical trial imaging solutions deliver special performance advantages compared to other image service providers that offer common, everyday clinical trial imaging services.  For more information on VirtualScopics, Inc., please visit www.virtualscopics.com.

Forward-looking Statements
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby.  These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure, the strategic alliance with IXICO and new customer contract signings and awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions.  Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations.  Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.  Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov.  These include without limitation:  the risk of cancellation or delay of customer contracts or specifically as it relates to contract awards, the risk that they may not get signed.  Other risks include the Company's dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others.  All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.

For More Information, Contact:
Donna N. Stein, APR, Fellow PRSA
Managing Partner
Donna Stein & Partners
315-361-4672
Email:  dstein1@twcny.rr.com


'/>"/>
SOURCE VirtualScopics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. VirtualScopics Board of Directors Appoints Eric Converse Interim Chief Executive Officer, Announces Resignation of Jeff Markin
2. Dr. Prem Reddy Named Among Most Influential Physician Executives in Nation
3. Bayer Employees Named Rising Stars by Healthcare Businesswomens Association
4. Remedy Informatics Named "Cool Vendor" in Life Sciences by Leading Technology Analyst Firm
5. Dr. Phillip Chan Named Finalist for Ernst & Young Entrepreneur of the Year® 2012 Award in New Jersey
6. Dave Zitnak Of Upsher-Smith Laboratories Named Branded Representative Of The Year By McKesson Corporation
7. StreamVenue Healthcare CEO Named Peoples Choice Winner
8. Masimo CEO Joe Kiani Named Ernst & Young Entrepreneur of the Year
9. Prime Therapeutics Named a Top Workplace by the Minneapolis Star Tribune
10. WellTok Named Colorado Company to Watch for 2012
11. 3 Pediatric Centers that Offer SynCardia Total Artificial Heart Named in Top 10 for "Best Childrens Hospitals"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... the "Global Biosimilar Pipeline and Market Prospects: Addressing ... report to their offering. ... "Global Biosimilar Pipeline and Market ... by Design" provides an in-depth assessment of the current ...
(Date:4/20/2017)... , April 20, 2017  CVS Pharmacy, the ... unveiled a new store design to enhance the ... healthier food, health-focused products and expanded beauty selections ... help customers discover new offerings. Together with its ... evolution of the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, ... their offering. ... pharmacogenomics market was valued at US$ 7,167.6 Mn in 2015, ... expanding at a CAGR of 5.6% from 2016 to 2024. ...
Breaking Medicine Technology:
(Date:4/28/2017)... CA (PRWEB) , ... April 28, 2017 , ... ... pleased to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians ... experience, since it streamlines the reporting process and provides a familiar interface that ...
(Date:4/28/2017)... , ... April 28, 2017 , ... Horizon Blue Cross ... the company’s credit rating of “A” and its outlook as “stable.” At the same ... reserves, which have fallen in recent years, dip below “capital adequacy” thresholds required for ...
(Date:4/28/2017)... York, NY (PRWEB) , ... April 28, 2017 ... ... Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast U.S. ... recent hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically proven ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... Replace tubes . These lamps offer an instant energy-saving solution for F32T8 fluorescent ... rewire fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize the existing ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic ... has joined the revolutionary endoscopic practice under Dr. Datta. Patel is a Board ... Medicine. The patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is ...
Breaking Medicine News(10 mins):